Seguir
Christopher Melani
Christopher Melani
National Cancer Institute
Dirección de correo verificada de nih.gov - Página principal
Título
Citado por
Citado por
Año
Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma
MS Lionakis, K Dunleavy, M Roschewski, BC Widemann, JA Butman, ...
Cancer cell 31 (6), 833-843. e5, 2017
4532017
Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC …
K Dunleavy, MA Fanale, JS Abramson, A Noy, PF Caimi, S Pittaluga, ...
The Lancet Haematology 5 (12), e609-e617, 2018
1852018
Multicenter study of risk-adapted therapy with dose-adjusted EPOCH-R in adults with untreated Burkitt lymphoma
M Roschewski, K Dunleavy, JS Abramson, BL Powell, BK Link, P Patel, ...
Journal of clinical oncology 38 (22), 2519, 2020
1282020
Pathobiology and treatment of lymphomatoid granulomatosis, a rare EBV-driven disorder
C Melani, ES Jaffe, WH Wilson
Blood, The Journal of the American Society of Hematology 135 (16), 1344-1352, 2020
832020
End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making
C Melani, R Advani, M Roschewski, KM Walters, CC Chen, L Baratto, ...
Haematologica 103 (8), 1337, 2018
762018
PD-1 blockade in mediastinal gray-zone lymphoma
C Melani, A Major, J Schowinsky, M Roschewski, S Pittaluga, ES Jaffe, ...
New England Journal of Medicine 377 (1), 89-91, 2017
672017
Gene expression profiling of mediastinal gray zone lymphoma and its relationship to primary mediastinal B-cell lymphoma and classical Hodgkin lymphoma
S Pittaluga, A Nicolae, GW Wright, C Melani, M Roschewski, S Steinberg, ...
Blood cancer discovery 1 (2), 155-161, 2020
372020
Molecular monitoring of cell-free circulating tumor DNA in non-Hodgkin lymphoma.
C Melani, M Roschewski
Oncology 30 (8), 731-731, 2016
212016
Molecular monitoring of cell-free circulating tumor DNA in non-Hodgkin lymphoma.
C Melani, M Roschewski
Oncology 30 (8), 731-731, 2016
212016
Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma
R Lakhotia, C Melani, K Dunleavy, S Pittaluga, N Saba, L Lindenberg, ...
Blood Advances 6 (8), 2667-2680, 2022
202022
Phase 1b/2 study of vipor (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide) in relapsed/refractory B-cell lymphoma: safety, efficacy and molecular analysis
C Melani, R Lakhotia, S Pittaluga, MD Miljkovic, JD Phelan, JR Muppidi, ...
Blood 136, 44-45, 2020
202020
Liquid biopsy in non‐Hodgkin's lymphoma
C Melani, WH Wilson, M Roschewski
Hematological Oncology 37, 70-74, 2019
202019
MYC gene rearrangement in diffuse large B-cell lymphoma does not confer a worse prognosis following dose-adjusted EPOCH-R
C Lai, M Roschewski, C Melani, S Pittaluga, M Shovlin, SM Steinberg, ...
Leukemia & lymphoma 59 (2), 505-508, 2018
182018
Risk-adapted therapy in adults with Burkitt lymphoma: results of NCI 9177, a multicenter prospective phase II study of DA-EPOCH-R
M Roschewski, K Dunleavy, JS Abramson, BK Link, S Parekh, ...
Blood 130, 188, 2017
182017
Risk‐adapted therapy in adults with burkitt lymphoma: updated results of a multicenter prospective phase II study of DA‐EPOCH‐R
K Dunleavy, M Roschewski, JS Abramson, B Link, S Parekh, ...
Hematological Oncology 35, 133-134, 2017
162017
Next-generation sequencing–based monitoring of circulating tumor DNA reveals clonotypic heterogeneity in untreated PTCL
MD Miljkovic, C Melani, S Pittaluga, R Lakhotia, N Lucas, A Jacob, ...
Blood Advances 5 (20), 4198-4210, 2021
152021
Circulating tumor DNA dynamics during therapy predict outcomes in mantle cell lymphoma
R Lakhotia, C Melani, S Pittaluga, K Dunleavy, NS Saba, AN Lucas, ...
Blood 132 (Supplement 1), 147-147, 2018
132018
Next-generation sequencing based monitoring of circulating-tumor DNA in untreated peripheral T-cell lymphoma
C Melani, S Pittaluga, L Yee, A Lucas, M Shovlin, A Jacob, K Chan, ...
Blood 130, 2728, 2017
112017
Phase 1 study of escalating doses of ibrutinib and temozolomide, etoposide, liposomal doxorubicin, dexamethasone, rituximab (TEDDI-R) with isavuconazole for relapsed and …
M Roschewski, C Melani, R Lakhotia, S Pittaluga, JD Phelan, C Peer, ...
Blood 136, 12-13, 2020
102020
Phase I dose escalation study of the anti-CD2 monoclonal antibody, siplizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas
J Roswarski, M Roschewski, A Lucas, C Melani, S Pittaluga, ES Jaffe, ...
Leukemia & lymphoma 59 (6), 1466-1469, 2018
102018
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20